SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Publication of Two Pivotal Phase III Studies of Regorafenib: Positive Phase III Data on Bayer Corporation's Regorafenib in Metastatic Colorectal Cancer (mCRC) and Gastrointestinal Stromal Tumor (GIST) Published in the Lancet